Z-Medica

Name

Z-Medica

Legal name

Z-Medica

Website

https://z-medica.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Short description

Z-Medica is a medical device company that develops FDA-cleared kaolin-based hemostatic products (QuikClot®) for controlling severe bleeding in hospitals, EMS, law enforcement, and military settings. Operating as a subsidiary of Teleflex Incorporated, it sells through direct B2B enterprise and government channels globally.

Ownership category

akta.pro rank

Product category

Hemostatic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Surgical Stapling, Suturing & Hemostasis (Staplers, Clips, Sealants, Tourniquets) (HLAHADAL)

Keywords

• Hemostatic dressings
• Bleeding control devices
• Kaolin gauze
• Trauma care products
• Interventional hemostasis

Headquarters

HQ city

Wallingford

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Hemostatic Medical Devices: Sale of QuikClot branded hemostatic products including Combat Gauze, QuikClot Control+, and Interventional devices for bleeding control in medical, military, and emergency response settings.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Z-Medica manufactures and sells QuikClot branded hemostatic medical devices—kaolin-impregnated gauze dressings, hemostatic pads, and interventional products—that activate Factor XII to accelerate the clotting cascade and achieve faster bleeding control. Products are sold for hospital (OR, Cath Lab, ICU, ED), EMS & fire rescue, law enforcement, and military use. Federal (USA) law restricts sale or use of these devices to physicians or by the order of a physician.

Product overview

Z-Medica's QuikClot is a portfolio of proprietary kaolin-based hemostatic products designed to control bleeding faster than standard methods. The core technology consists of a non-woven material impregnated with Kaolin, which activates Factor XII and accelerates the clotting cascade. The product line includes QuikClot Control+ (hospital hemostatic dressing), QuikClot Combat Gauze (military/tactical gauze), and QuikClot Radial (cath lab device), serving four market segments: Hospital (OR, Cath Lab, ICU, ED), EMS & Fire Rescue, Law Enforcement, and Military. Clinical evidence demonstrates 88-92% faster time to hemostasis and up to 39% less blood loss compared to standard care.

Differentiator

Problem solved

Functional benefit

Brands

• QuikClot®: Proprietary hemostatic agent technology using kaolin-impregnated material to accelerate clotting and control bleeding faster.

Products and services

• QuikClot Control+® A kaolin-based hemostatic dressing indicated for hospital bleeding control, shown in clinical studies to achieve up to 39% less blood loss compared to standard care. For use by or on the order of a physician.
• QuikClot Combat Gauze® A kaolin-impregnated gauze bandage used by military and first responders for hemorrhage control in traumatic injuries, with 95% successful hemostasis reported in the Mayo Clinic Prehospital study and 91% in the Israeli Defense Forces study.
• QuikClot Radial® A kaolin-based hemostatic pad designed for transradial access procedures in catheterization labs, demonstrating savings of 89 minutes versus TR band compression and 17 minutes versus manual compression.
• QuikClot Interventional® QuikClot interventional hemostatic products intended for catheterization lab use, leveraging the kaolin-based technology to accelerate hemostasis after percutaneous procedures.

Quantifiable outcome

• 88%-92% faster time to hemostasis compared to standard gauze
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Stop The BleedcoreGTM or Marketing PartnerZ-Medica is an official partner of the Stop The Bleed program, a national initiative that trains civilians in bleeding control. The partnership supports public safety education and extends QuikClot's reach to broader community bleeding control awareness.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Celox Medical: Celox manufactures chitosan-based hemostatic gauze and granules used by military and emergency responders for rapid bleeding control. Direct competitor to QuikClot in prehospital and tactical hemostasis, addressing the same combat and trauma applications with a different active mechanism.
• Tricol Biomedical (HemCon): Tricol Biomedical produces HemCon chitosan-based hemostatic dressings and bandages used in military and civilian trauma care. Directly comparable to QuikClot Combat Gauze as a competing hemostatic technology marketed to the same military, EMS, and law enforcement buyers.

Broad incumbents

• Baxter International: Baxter markets FloSeal hemostatic matrix and other surgical hemostasis products used in operating rooms and hospitals. A broad incumbent medical device company competing in surgical hemostasis with overlapping OR and cath lab customer relationships.
• Ethicon (Johnson & Johnson): Ethicon manufactures Surgicel oxidized cellulose hemostatic products used across surgical specialties. As a J&J surgical franchise, it competes with QuikClot for hospital OR and surgical hemostasis share through established surgeon relationships and formulary presence.
• Integra LifeSciences: Integra LifeSciences offers a portfolio of hemostasis products including oxidized cellulose and collagen-based agents sold to hospitals and surgical centers. A diversified medtech incumbent with overlapping surgical hemostasis sales channels.
• Becton Dickinson (BD): BD provides hemostatic and tissue sealing products, along with surgical instruments, sold to hospitals and surgical centers globally. Large incumbent with broad hospital channel reach comparable to the buyer set served by QuikClot's hospital line.
• Teleflex Incorporated: Teleflex is Z-Medica's parent company and a global medical technology company with vascular access, surgical, and anesthesia portfolios. Relevant as the corporate owner controlling QuikClot strategy and as a broad incumbent providing commercial scale in overlapping hospital markets.
• Medtronic: Medtronic operates broad surgical, vascular, and patient monitoring franchises that touch the same OR, cath lab, and ICU buyers served by QuikClot's hospital products. While not a direct hemostatic gauze competitor, it is a broad incumbent with overlapping hospital decision-maker relationships and channel access.

Emerging players

• Marine Polymer Technologies: Marine Polymer Technologies develops poly-N-acetyl glucosamine based hemostatic dressings for wound and bleeding control. An emerging player with overlapping hemostatic technology but more limited commercial scale than QuikClot's installed base.
• Arch Therapeutics: Arch Therapeutics develops self-assembling peptide-based hemostatic and sealant products (AC5) for surgical and trauma use. An emerging player with a novel mechanism targeting the same hemostatic use cases served by QuikClot in OR and trauma settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/zmedica
• LinkedInlinkedin.com/company/z-medica

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Z-Medica